XML 126 R82.htm IDEA: XBRL DOCUMENT
v3.22.4

Segment information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Operating Segments [Abstract] |
Summary of Net Sales by Segment and Geographical Area | The table below sets forth Sanofi’s net sales for the years ended December 31, 2022, 2021 and 2020:
(€ million) | Europe | United States | Other countries | 2022 | Europe | United States | Other countries | 2021 | Europe | United States | Other countries | 2020
Pharmaceuticals | 7,157 |  | 13,694 |  | 9,837 |  | 30,688 |  | 7,201 |  | 10,484 |  | 9,285 |  | 26,970 |  | 6,819 |  | 9,635 |  | 9,220 |  | 25,674 |
Dupixent® | 940 |  | 6,346 |  | 1,007 |  | 8,293 |  | 649 |  | 3,971 |  | 629 |  | 5,249 |  | 386 |  | 2,808 |  | 340 |  | 3,534 |
Neurology & Immunology | 639 |  | 1,637 |  | 174 |  | 2,450 |  | 638 |  | 1,482 |  | 204 |  | 2,324 |  | 578 |  | 1,631 |  | 185 |  | 2,394 |
of which | Aubagio® | 511 |  | 1,420 |  | 100 |  | 2,031 |  | 512 |  | 1,312 |  | 131 |  | 1,955 |  | 473 |  | 1,448 |  | 124 |  | 2,045 |
Rare Diseases | 1,104 |  | 1,367 |  | 974 |  | 3,445 |  | 1,069 |  | 1,142 |  | 915 |  | 3,126 |  | 1,010 |  | 1,122 |  | 879 |  | 3,011 |
of which | Cerezyme® | 239 |  | 194 |  | 274 |  | 707 |  | 244 |  | 173 |  | 266 |  | 683 |  | 249 |  | 177 |  | 264 |  | 690 |
| Fabrazyme® | 228 |  | 471 |  | 239 |  | 938 |  | 223 |  | 395 |  | 226 |  | 844 |  | 200 |  | 406 |  | 211 |  | 817 |
| Myozyme®/ Lumizyme® | 408 |  | 318 |  | 232 |  | 958 |  | 410 |  | 373 |  | 220 |  | 1,003 |  | 389 |  | 359 |  | 200 |  | 948 |
Oncology | 239 |  | 515 |  | 198 |  | 952 |  | 327 |  | 410 |  | 175 |  | 912 |  | 299 |  | 368 |  | 131 |  | 798 |
of which | Jevtana® | 33 |  | 275 |  | 83 |  | 391 |  | 112 |  | 253 |  | 90 |  | 455 |  | 187 |  | 246 |  | 103 |  | 536 |
Rare Blood Disorders | 94 |  | 983 |  | 240 |  | 1,317 |  | 81 |  | 842 |  | 218 |  | 1,141 |  | 41 |  | 837 |  | 339 |  | 1,217 |
of which | Alprolix® | — |  | 406 |  | 98 |  | 504 |  | — |  | 332 |  | 82 |  | 414 |  | — |  | 320 |  | 146 |  | 466 |
| Eloctate® | — |  | 450 |  | 130 |  | 580 |  | — |  | 429 |  | 134 |  | 563 |  | — |  | 445 |  | 193 |  | 638 |
Core Assets | 1,917 |  | 1,653 |  | 2,819 |  | 6,389 |  | 1,868 |  | 1,315 |  | 2,585 |  | 5,768 |  | 1,759 |  | 1,413 |  | 2,409 |  | 5,581 |
of which | Lovenox® | 658 |  | 17 |  | 635 |  | 1,310 |  | 703 |  | 29 |  | 754 |  | 1,486 |  | 656 |  | 30 |  | 665 |  | 1,351 |
| Toujeo® | 421 |  | 283 |  | 413 |  | 1,117 |  | 394 |  | 259 |  | 316 |  | 969 |  | 374 |  | 267 |  | 292 |  | 933 |
| Plavix® | 101 |  | 9 |  | 873 |  | 983 |  | 115 |  | 9 |  | 805 |  | 929 |  | 126 |  | 10 |  | 777 |  | 913 |
Non-Core Assets | 1,637 |  | 1,176 |  | 4,409 |  | 7,222 |  | 1,846 |  | 1,281 |  | 4,515 |  | 7,642 |  | 2,088 |  | 1,389 |  | 4,849 |  | 8,326 |
of which | Lantus® | 426 |  | 757 |  | 1,076 |  | 2,259 |  | 474 |  | 861 |  | 1,159 |  | 2,494 |  | 537 |  | 929 |  | 1,195 |  | 2,661 |
| Other non-core assets | 1,129 |  | 412 |  | 2,944 |  | 4,485 |  | 1,285 |  | 410 |  | 3,034 |  | 4,729 |  | 1,451 |  | 438 |  | 3,222 |  | 5,111 |
Industrial sales | 587 |  | 17 |  | 16 |  | 620 |  | 723 |  | 41 |  | 44 |  | 808 |  | 658 |  | 67 |  | 88 |  | 813 |
Vaccines | 1,341 |  | 3,291 |  | 2,597 |  | 7,229 |  | 1,225 |  | 2,762 |  | 2,336 |  | 6,323 |  | 973 |  | 2,759 |  | 2,241 |  | 5,973 |
of which | Polio/Pertussis/ Hib Vaccines | 325 |  | 456 |  | 1,504 |  | 2,285 |  | 306 |  | 470 |  | 1,383 |  | 2,159 |  | 331 |  | 412 |  | 1,363 |  | 2,106 |
| Influenza Vaccines | 681 |  | 1,737 |  | 559 |  | 2,977 |  | 729 |  | 1,366 |  | 533 |  | 2,628 |  | 441 |  | 1,575 |  | 456 |  | 2,472 |
Consumer Healthcare(a) | 1,501 |  | 1,290 |  | 2,289 |  | 5,080 |  | 1,333 |  | 1,139 |  | 1,996 |  | 4,468 |  | 1,359 |  | 1,071 |  | 1,964 |  | 4,394 |
of which | Allergy | 55 |  | 439 |  | 240 |  | 734 |  | 49 |  | 371 |  | 192 |  | 612 |  | 51 |  | 361 |  | 205 |  | 617 |
| Pain Care | 555 |  | 212 |  | 446 |  | 1,213 |  | 515 |  | 196 |  | 382 |  | 1,093 |  | 481 |  | 181 |  | 389 |  | 1,051 |
| Digestive Wellness | 432 |  | 144 |  | 742 |  | 1,318 |  | 389 |  | 124 |  | 618 |  | 1,131 |  | 371 |  | 85 |  | 532 |  | 988 |
Total net sales | 9,999 |  | 18,275 |  | 14,723 |  | 42,997 |  | 9,759 |  | 14,385 |  | 13,617 |  | 37,761 |  | 9,151 |  | 13,465 |  | 13,425 |  | 36,041 |
(a) For the Consumer Healthcare GBU, Sanofi has since 2021 adopted a more granular presentation by introducing new sub-categories that reflect consumer trends and the strengths and opportunities of the portfolio.
Schedule of Segment Results | The table below shows Sanofi’s segment results for the years ended December 31, 2022, December 31, 2021 and December 31, 2020:
| 2022
(€ million) | Pharmaceuticals | Vaccines | Consumer Healthcare | Other(a) | Total Sanofi
Net sales | 30,688 |  | 7,229 |  | 5,080 |  | — |  | 42,997 |
Other revenues | 657 |  | 1,666 |  | 62 |  | 7 |  | 2,392 |
Cost of sales | (7,511) |  | (4,101) |  | (1,827) |  | (253) |  | (13,692) |
Research and development expenses | (5,067) |  | (936) |  | (187) |  | (516) |  | (6,706) |
Selling and general expenses | (5,923) |  | (870) |  | (1,478) |  | (2,221) |  | (10,492) |
Other operating income and expenses | (1,800) |  | 132 |  | 152 |  | 2 |  | (1,514) |
Share of profit/(loss) from investments accounted for using the equity method | 28 |  | 48 |  | 12 |  | — |  | 88 |
Net income attributable to non-controlling interests | (29) |  | — |  | (4) |  | — |  | (33) |
Business operating income | 11,043 |  | 3,168 |  | 1,810 |  | (2,981) |  | 13,040 |
(a) This caption reconciles segment financial information to total consolidated financial information.
| 2021
(€ million) | Pharmaceuticals | Vaccines | Consumer Healthcare | Other(a) | Total Sanofi
Net sales | 26,970 |  | 6,323 |  | 4,468 |  | — |  | 37,761 |
Other revenues | 264 |  | 1,095 |  | 55 |  | — |  | 1,414 |
Cost of sales | (6,965) |  | (3,430) |  | (1,606) |  | (250) |  | (12,251) |
Research and development expenses | (4,330) |  | (712) |  | (153) |  | (497) |  | (5,692) |
Selling and general expenses | (5,326) |  | (805) |  | (1,388) |  | (2,036) |  | (9,555) |
Other operating income and expenses | (1,172) |  | 128 |  | 111 |  | (13) |  | (946) |
Share of profit/(loss) from investments accounted for using the equity method | 17 |  | 11 |  | 11 |  | — |  | 39 |
Net income attributable to non-controlling interests | (49) |  | (1) |  | (5) |  | (1) |  | (56) |
Business operating income | 9,409 |  | 2,609 |  | 1,493 |  | (2,797) |  | 10,714 |
(a) This caption reconciles segment financial information to total consolidated financial information.
| 2020(a)(b)
(€ million) | Pharmaceuticals | Vaccines | Consumer Healthcare | Other(c) | Total Sanofi
Net sales | 25,674 |  | 5,973 |  | 4,394 |  | — |  | 36,041 |
Other revenues | 128 |  | 1,141 |  | 59 |  | — |  | 1,328 |
Cost of sales | (6,982) |  | (3,312) |  | (1,528) |  | (284) |  | (12,106) |
Research and development expenses | (4,171) |  | (682) |  | (153) |  | (524) |  | (5,530) |
Selling and general expenses | (4,927) |  | (789) |  | (1,419) |  | (2,256) |  | (9,391) |
Other operating income and expenses | (487) |  | 3 |  | 53 |  | (130) |  | (561) |
Share of profit/(loss) from investments accounted for using the equity method | 5 |  | 2 |  | 9 |  | — |  | 16 |
Net income attributable to non-controlling interests | (33) |  | — |  | (5) |  | — |  | (38) |
Business operating income | 9,207 |  | 2,336 |  | 1,410 |  | (3,194) |  | 9,759 |
(a) 2020 figures have been adjusted to take account of the reallocation of certain expenses (in particular IT costs related to Sanofi’s new digital organization) from the Pharmaceuticals, Vaccines and Consumer Healthcare operating segments to the “Other” segment. (b) Includes the impact of the April 2021 IFRIC agenda decision on the allocation of benefits to service periods, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021. (c) This caption reconciles segment financial information to total consolidated financial information.
Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method | The table below, presented in compliance with IFRS 8, shows a reconciliation between aggregated “Business operating income” for the segments and Income before tax and investments accounted for using the equity method:
(€ million) | 2022 | 2021 | 2020 | (h) |
Business operating income | 13,040 |  | 10,714 |  | 9,759 |  |  |
Share of profit/(loss) from investments accounted for using the equity method(a) | (88) |  | (39) |  | (16) |  |  |
Net income attributable to non-controlling interests(b) | 33 |  | 56 |  | 38 |  |  |
Amortization and impairment of intangible assets (c) | (1,599) |  | (1,772) |  | (2,011) |  |  |
Fair value remeasurement of contingent consideration | 27 |  | (4) |  | 124 |  |  |
Expenses arising from the impact of acquisitions on inventories(d) | (3) |  | (4) |  | (53) |  |  |
Restructuring costs and similar items | (1,336) |  | (820) |  | (1,089) |  |  |
Other gains and losses, and litigation(e) | (370) |  | (5) |  | 136 |  |  |
Gain on divestment of Regeneron shares on May 29, 2020(f) | — |  | — |  | 7,225 |  |  |
Income from out-licensing(g) | 952 |  | — |  | — |  |  |
Operating income | 10,656 |  | 8,126 |  | 14,113 |  |  |
Financial expenses | (440) |  | (368) |  | (388) |  |  |
Financial income | 206 |  | 40 |  | 53 |  |  |
Income before tax and investments accounted for using the equity method | 10,422 |  | 7,798 |  | 13,778 |  |  |
(a) Excludes restructuring costs relating to investments accounted for using the equity method and expenses arising from the impact of acquisitions on investments accounted for using the equity method. For the first two quarters of 2020, this line has been restated to exclude any effect of equity method accounting for the investment in Regeneron following the divestment of Sanofi's entire equity interest (with the exception of the 400,000 shares retained by Sanofi) on May 29, 2020. (b) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (c) For 2022, this line includes a reversal of €2,154 million on Eloctate franchise products following FDA approval of ALTUVIIIO TM dated February 22, 2023, partially offset by an impairment of €1,586 million relating to the development project for SAR444245 (non-alpha interleukin-2). (d) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date. (e) For 2020, this line mainly comprises the gain on the sale of operations related to the Seprafilm® activity to Baxter. (f) This line includes the gain on the sale of (i) 13 million shares of Regeneron common stock in the registered public offering and (ii) the 9.8 million shares repurchased by Regeneron, but does not include the gain arising from the remeasurement of the 400,000 retained shares at market value as of May 29, 2020. (g) For 2022, this line includes an upfront payment of $900 million and a regulatory milestone payment of $100 million related to the out-licensing of Libtayo® following the restructuring of the Immuno-Oncology Collaboration and License Agreement with Regeneron (see Note C.1.). (h) Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment | Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.
| 2022
(€ million) | Pharmaceuticals | Vaccines | Consumer Healthcare | Total
Investments accounted for using the equity method | 536 |  | 104 |  | 37 |  | 677 |
Acquisitions of property, plant and equipment | 1,025 |  | 504 |  | 77 |  | 1,606 |
Acquisitions of other intangible assets | 463 |  | 111 |  | 21 |  | 595 |
| 2021
(€ million) | Pharmaceuticals | Vaccines | Consumer Healthcare | Total
Investments accounted for using the equity method | 159 |  | 91 |  | — |  | 250 |
Acquisitions of property, plant and equipment | 1,024 |  | 382 |  | 73 |  | 1,479 |
Acquisitions of other intangible assets(a) | 450 |  | 108 |  | 6 |  | 564 |
(€ million) | 2020
Pharmaceuticals | Vaccines | Consumer Healthcare | Total
Investments accounted for using the equity method | 154 |  | 47 |  | — |  | 201 |
Acquisitions of property, plant and equipment | 755 |  | 404 |  | 95 |  | 1,254 |
Acquisitions of other intangible assets(a) | 501 |  | 322 |  | 6 |  | 829 |
(a) Includes the impact of the IFRIC agenda decision of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
Summary of Geographical Information on Net Sales and Non-Current Assets | The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS 16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.
| 2022
(€ million) | Total | Europe | of which France | North America | of which United States | Other countries
Net sales | 42,997 |  | 9,999 |  | 2,296 |  | 18,984 |  | 18,275 |  | 14,014 |
Non-current assets: |  |  |  |  |  |
•property, plant and equipment owned | 9,869 |  | 5,365 |  | 2,875 |  | 3,284 |  | 2,457 |  | 1,220 |
•goodwill | 49,892 |  | — |  | — |  | — |  | — |  | — |
▪other intangible assets | 21,640 |  | 6,257 |  | — |  | 14,178 |  | — |  | 1,205 |
| 2021
Total | Europe | of which France | North America | of which United States | Other countries
Net sales | 37,761 |  | 9,759 |  | 2,256 |  | 15,075 |  | 14,385 |  | 12,927 |
Non-current assets: |  |  |  |  |  |
•property, plant and equipment owned | 10,028 |  | 5,959 |  | 3,253 |  | 2,998 |  | 2,234 |  | 1,071 |
•goodwill | 48,056 |  | — |  | — |  | — |  | — |  | — |
•other intangible assets(a) | 21,407 |  | 7,059 |  | — |  | 13,187 |  | — |  | 1,161 |
(€ million) | 2020
Total | Europe | of which France | North America | of which United States | Other countries
Net sales | 36,041 |  | 9,151 |  | 2,223 |  | 14,060 |  | 13,465 |  | 12,830 |
Non-current assets: |  |  |  |  |  |
•property, plant and equipment owned | 9,365 |  | 5,895 |  | 3,189 |  | 2,542 |  | 1,899 |  | 928 |
•goodwill | 44,364 |  | — |  | — |  | — |  | — |  | — |
•other intangible assets(a) | 18,341 |  | 6,208 |  | — |  | 10,665 |  | — |  | 1,468 |
(a) Includes the impact of the IFRIC agenda decision of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.

X
- Definition The disclosure of geographical information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 33 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfGeographicalAreasExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 23 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment. + References No definition available. + Details
Name: | sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of net sales by segment and geographical area. + References No definition available. + Details
Name: | sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments reconciling items. + References No definition available. + Details
Name: | sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Operating Segments [Abstract] + References No definition available. + Details
Name: | sny_OperatingSegmentsAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration